Abstract
By exhibiting resistance to most known antibiotics or quickly acquiring resistance to antimicrobials it was once susceptible to, Acinetobacter baumannii has attracted increasing attention worldwide since the last decades of the previous century. The resistance abilities of the bacterium were soon shown to be so advanced that it was even able to resist antibiotics that had only just been discovered and used for first time. Utilizing complex mechanisms of resistance, combining different modalities, and achieving new resistant traits established A. baumannii as one of the most clinically important and challenging pathogens of the new century, being categorized by the World Health Organization as a critical priority bacterium for which new antibiotics are urgently needed. After even last-resort, broad-spectrum antibiotics were rendered useless, the fight against this superbug began to be led by the reintroduction of once abandoned antimicrobials, new combination therapies and novel modalities of treatment. In this chapter, we will look at the history and background of Acinetobacter species and then specifically focus on A. baumannii, explaining its clinical importance in detail, reviewing the most recent findings regarding its mechanisms of resistance, latest modalities of treatment and newest areas of research towards opening new frontiers in the management of infections caused by multi-resistant strains of this bacterium.
Keywords
- Acinetobacter baumannii
- antimicrobial resistance
- carbapenem resistance
- ESKAPE bacteria
- health-associated infections
1. Introduction
The story of the Acinetobacter genus dates back to the early 20th century when in 1911, Dutch microbiologist Martinus Willem Beijerinck named a newly discovered organism isolated from soil using minimal media enriched with calcium acetate:
In 1954 Brisou and Prévot coined the name Acinetobacter from the Greek “ακινɛτοσ” [akinetos], meaning non-motile, to separate non-motile from motile microorganisms within the genus Achromobacter [3]. Years later in 1968 Paul Baumann, through a comprehensive survey, suggested that all of the above-listed species belonged to a single genus and could not be further sub-classified into different species based on the phenotypical characteristics, for which the name Acinetobacter was proposed [4]. In 1971, based on the results of Baumann’s publication subcommittee on nomenclature of Moraxella and allied bacteria, the genus Acinetobacter was officially acknowledged [5]. In 1974 the genus Acinetobacter was listed in Bergey’s manual of systematic bacteriology, described as a single species named
Acinetobacter are defined as gram negative (however, since Acinetobacter species are often difficult to de-stain through the process of Gram staining, they are often incorrectly identified as gram positive), strictly aerobic, catalase-positive, oxidase-negative, non-motile, non-fermenting, non-fastidious bacteria with a DNA G + C content of 39–47% [7]. Acinetobacter has been classified in the family
By 2015 only 33 species of Acinetobacter had been identified. Rapid technological advances in recent years have caused faster and more precise identification of novel strains. Continued reports of such novel strains have doubled the number of described species in the last 6 years. Within the 4 years from 2017 to 2020 alone, 22 new Acinetobacter species were identified [9]. By May 2021 67 Acinetobacter species had already been validly named, and 20 additional species were under tentative species designation. Most identified species, however, are non-pathogenic, environmental microorganisms [9].
Smith et al., performed and published the first whole genome sequencing of
Traditionally four species of Acinetobacter
Although until 1975
The range of
In this chapter, we describe the latest findings regarding the pathogenicity and mechanisms of antibiotic resistance of
2. Clinical relevance and mechanisms of the pathogenicity of A. baumannii
The survival of
The most important and common manifestations of
The mortality rate of
The virulence of
Adhesion and invasion: Outer membrane proteins (OMPs) are by far the most well studied structures of the bacterium, contributing to cell adhesion, invasion, and cytotoxicity [27]. OmpA (also known as Omp38), a conserved, abundant porin with a molecular weight of 38 kDa, is one of the adhesins which plays an essential role in the bacterium’s adhesion and cell invasion [27]. After attachment of
Recently, the response regulator BfmR and the sensor kinase BfmS, in the two-component regulatory system BfmRS, have been shown to play a role, as non-OMP adhesins, in cell attachment of the bacterium [34]. The two-component regulatory system BfmRS can sense extracellular signals important in the formation of biofilm, causing expressions of the chaperone-usher assembly system accountable for the formation of pili (the needed component for biofilm formation on polystyrene surfaces). It has been suggested that pili may be relevantly attributed to bacterial attachment in biotic and abiotic surfaces [8]. Some of those indicators include the ability of
Phospholipase enzymes play a significant role in the bacteria’s invasion ability [8]. Both phospholipase C (PLC) and phospholipase D (PLD) inactivation lead to impaired cell invasion [38]. Phospholipases are essential enzymes necessary for the metabolism of phosphatidylcholine and the release of phosphorylated head groups and polar head groups from PLD trough PLC cleavage, imposing change in the constancy of the membrane of host cells [38] and so facilitating invasion. OMPs containing phosphorylcholine contribute to
To date, our understanding of host cell receptors’ contribution in bacteria’s adhesion and invasion is still very limited.
2.1 Cytotoxins
Other than the already-mentioned cytotoxic abilities of OmpA, Omp33 and Ata, the lipopolysaccharide (LPS) envelope of
γ-glutamyl transferase enzyme (GGT), a secretion from the type II secretion system, is another protein that contributes to the bacteria’s cytotoxicity via caspase activation leading to ATP depletion followed by cell-cycle arrest and apoptosis [43]. It has been shown that strains of
2.2 Serum persistence
In addition to the mentioned mechanisms, serum persistence indirectly affects the pathogenicity of the bacterium [8]. Capsular exopolysaccharide (CPS) is an important component mediating in persistence and hence, better survival of many invasive bacteria under unfavorable and harsh conditions, protecting them from phagocytosis of humoral immune attacks and inhibiting activation of alternative complement pathway [46] (an ability reported from OmpA proteins as well [47]). Although many isolates of
The ability of the bacterium to degrade H2O2, utilized by catalases KatE and KatG, which could decrease production of reactive oxygen species by the innate immune system, is another mechanism used by
Mutation of LpsB glycosyltransferase involved in LPS synthesis caused a reduction in the resistance of
Finally, metal acquisition systems, the BfmRS system through biofilm formation, phospholipases, and the novel plasminogen protein CipA all were shown to have an effect on the bacteria’s ability to survive longer in vivo [49, 51]. CipA links to the active form of plasmin and plasminogen, leading to a breakdown of fibrinogen, facilitating the spread of bacteria [49].
3. Mechanisms of resistance
Currently there are reports of isolates of
3.1 Resistance to beta-lactams
In
3.1.1 Beta-lactamases
Beta-lactamases are generally classified by two main schemes; the first one is the widely accepted Ambler Molecular classification scheme, which classifies enzymes based on their amino acid sequence, and the second one is the Bush-Jacoby classification scheme, which is based on biochemical characteristics of the enzymes [56, 57]. Ambler classification classifies beta-lactams into four major sub-classes A, B, C, and D based on their distinguishing amino acid motifs. Class A, C, and D are serin carbapenemases, achieving their effect through hydrolysing their substrate by the active site, forming acyl groups for which they need serin as a cofactor. Class B are collectively called bacterial metallo beta-lactamases (MBLs), using at least one zinc ion in their active site to hydrolyse beta-lactam antibiotics. MBLs are further subdivided into the three subclasses of B1, B2, and B3 [57]. Bush-Jacoby classification classifies these enzymes into the three subgroups of 1 (cephalosporinases, equivalent of class C), group 2 (serin beta-lactamases, equivalent of class A and D), and group 3 (MBLs, equivalent of class B) [56].
AmpC cephalosporinase, from the molecular class C beta lactamase, is the most prevalent enzyme utilized by
3.1.2 Target alteration of the antibiotics and modification in membrane permeability
Reduced expression of OMPs and alteration in penicillin-binding proteins (PBPs) are two mechanisms used by
PBPs play a crucial role in the synthesis of peptidoglycan used in the bacterial cell wall. They also catalyze transglycosylation and the cross-linking by transpeptidation of peptidoglycan.
3.1.3 Increased efflux pumps
So far, six families of efflux pumps have been identified: the resistance nodulation cell division family, the small multidrug resistance superfamily, the ATP-binding cassette (ABC) family, the major facilitator superfamily, the multidrug toxic compound extrusion family, and the recently identified proteobacterial antimicrobial compound efflux family [67]. The presence of efflux pumps provides resistance to multiple classes of antibiotics. The AdeABC efflux pump, a member of the resistance nodulation cell division family, is one of most studied and well-defined pumps in
3.2 Resistance to aminoglycosides
Most frequently,
The bacterium uses alteration of the target ribosomal protein as the other mechanism for resistance against this class of antibiotics [71]. 16S rRNA methylation has been described for
3.3 Resistance to quinolones
Mutations in the gyrA and parC genes, resulting in phenotypic changes in DNA gyrase and topoisomerase IV causing reduced drug affinity by interference with target site binding, are the main mechanisms used by
3.4 Resistance to colistin
Chromosomal DNA genes of the bacterium encode resistance to colistin via two mechanisms, target modification and remodeling of the outer membrane. The first mechanism is due to mutation in lipid A encoding genes (namely lpxA, lpxC, and lpxD) resulting in loss of LPS, which is an initial target for colistin [78]. The two-component system pmrAB (a response regulator and sensor kinase), in response to environmental conditions such as change in pH, Mg2+, and Fe3+, regulates the expression of genes causing synthesis of lipid A. Point mutation (as the second mechanism) in pmrA and pmrB causes upregulation of their gene expression and hence, remodeling of the outer membrane [79].
3.5 Resistance to Tetracyclines
Efflux and ribosomal protection are two mechanisms used for resistance against tetracyclines by
3.6 Resistance to trimethoprim-sulfamethoxazole and chloramphenicol
Resistant gene-containing integrons are very commonly seen among multidrug-resistant strains of the bacterium. The 3′-conserved region of an integron containing a qac gene fused to a sul gene has been shown to provide resistance to sulphonamides [83]. Similarly, the trimethoprim-resistant gene (dhfr) and chloramphenicol resistant gene (cat) are located on integron structures [70]. Efflux pumps also contribute to conferring resistance to these antibiotics [53].
4. Antibiotic treatment options for multi-resistant strains of A. baumannii and new non-antibiotic modalities under development
4.1 Antibiotic treatment
4.1.1 Carbapenems
For years carbapenems were a mainstay of antimicrobial therapy against
4.1.2 Polymyxins Colistin (polymyxin E)
Polymyxins are bactericidal antibiotics that function through cell membrane disruption. Polymyxins’ positively charged cationic region bind to the negatively charged hydrophilic part of LPS, causing loss of integrity of the cell membrane [88]. The emergence of pan-resistant strains of
4.1.3 Tetracyclines minocycline: tigecycline
Tetracyclines function by entering the outer membrane of gram-negative bacteria via protein channels, causing conformational changes in the RNA of the bacteria by binding to its 30S ribosomal unit [99], blocking entry of aminoacyl transferase RNA into the site A of the ribosome and consequently stopping protein production [99]. Since minocycline is a more lipophilic type (along with doxycycline) among tetracyclines, this antibiotic has better tissue penetration and antimicrobial activity [99]. As mentioned in the mechanisms of resistance section of this chapter, the main mechanism of resistance against tetracyclines is efflux of the drug by
4.2 Bacteriophages
In 2010 the first report of isolation and characterization of phage against
4.3 Monoclonal antibodies
Neutralizing virulence factors of the bacterium by the binding of monoclonal antibodies is the mainstay mechanism of action of these molecules against
4.4 Antimicrobial peptides
Antimicrobial peptides (AMPs) are products of eukaryotic and prokaryotic organisms as part of their innate host immune response [13]. Since they have bactericidal capacities and are broad spectrum, with low immunogenicity and low resistance, interest in them has been increasingly rising in recent years as alternatives to antibiotic treatment. As an example, efficacy of a hybrid of cecropin A and melittin has been reported in management of peritoneal sepsis caused by pan-resistant
4.5 Vaccination
Since
4.6 Other modalities
Some of the other modalities that have been explored in the clamor caused by the urgent need for a new treatment against multi-resistant
5. Conclusion
A. baumannii is one of the most complicated and challenging to treat pathogens of the modern era of medicine. The bacterium’s complex mechanisms of resistance, its genetic set-up, and its ability to survive on different surfaces and tolerate harsh environmental conditions make
References
- 1.
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii : Emergence of a successful pathogen. Clinical Microbiology Reviews. 2008;21 (3):538-582 - 2.
Henriksen SD. Moraxella, Acinetobacter, and the Mimeae. Bacteriological Reviews. 1973; 37 (4):522-561 - 3.
Brisou J, Prevot AR. Studies on bacterial taxonomy. X. The revision of species under Acromobacter group. Annales de l'Institut Pasteur. 1954; 86 (6):722-728 - 4.
Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). Journal of Bacteriology. 1968; 95 (5):1520-1541 - 5.
Lessel E. International Committee on Nomenclature of Bacteria Subcommittee on the Taxonomy of Moraxella and Allied Bacteria: Minutes of the meeting, 11 august 1970. Room constitution C, Maria-Isabel Hotel, Mexico City, Mexico. International Journal of Systematic and Evolutionary Microbiology. 1971; 21 (2):213-214 - 6.
Skerman VBD, McGowan V, Sneath PHA. Approved lists of bacterial names. International Journal of Systematic Bacteriology. 1980; 30 (1):225-230 - 7.
Howard A et al. Acinetobacter baumannii : An emerging opportunistic pathogen. Virulence. 2012;3 (3):243-250 - 8.
Ma C, McClean S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccine. 2021;9 (6):570 - 9.
Qin J et al. Precise species identification for Acinetobacter: A genome-based study with description of two novel Acinetobacter species. mSystems. 2021; 6 (3):e00237-e00221 - 10.
Smith MG et al. New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes & Development. 2007;21 (5):601-614 - 11.
Dexter C et al. Community-acquired Acinetobacter baumannii : Clinical characteristics, epidemiology and pathogenesis. Expert Review of Anti-Infective Therapy. 2015;13 (5):567-573 - 12.
Villalón P et al. Dynamics of a sporadic nosocomial Acinetobacter calcoaceticus - Acinetobacter baumannii Complex population. Frontiers in Microbiology. 2019;10 :593 - 13.
Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii : Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infection and Drug Resistance. 2018;11 :1249-1260 - 14.
Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Review of Anti-Infective Therapy. 2013; 11 (3):297-308 - 15.
Scott P et al. An outbreak of multidrug-resistant Acinetobacter baumannii -calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clinical Infectious Diseases. 2007;44 (12):1577-1584 - 16.
Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR. Morbidity and Mortality Weekly Report. 2004; 53 (45):1063-1066 - 17.
Elham B, Fawzia A. Colistin resistance in Acinetobacter baumannii isolated from critically ill patients: Clinical characteristics, antimicrobial susceptibility and outcome. African Health Sciences. 2019;19 (3):2400-2406 - 18.
Garcia Casallas JC et al. Bacteremia by colistin-resistant Acinetobacter baumannii isolate: A case report. Journal of Medical Case Reports. 2019;13 (1):141 - 19.
Papathanakos G et al. Colistin-resistant Acinetobacter baumannii bacteremia: A serious threat for critically ill patients. Microorganisms. 2020;8 (2):287 - 20.
Jung J, Park W. Acinetobacter species as model microorganisms in environmental microbiology: Current state and perspectives. Applied Microbiology and Biotechnology. 2015; 99 (6):2533-2548 - 21.
Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii : Evolution of a global pathogen. Pathogens and Disease. 2014;71 (3):292-301 - 22.
Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii : No longer a controversial issue. Critical Care. 2007;11 (3):134 - 23.
Falagas ME et al. Community-acquired Acinetobacter infections. European Journal of Clinical Microbiology & Infectious Diseases. 2007; 26 (12):857-868 - 24.
Chang WN et al. Community-acquired Acinetobacter meningitis in adults. Infection. 2000; 28 (6):395-397 - 25.
Greene C et al. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii . American Journal of Infection Control. 2016;44 (5):e65-e71 - 26.
Basri R et al. Burden of bacterial meningitis: A retrospective review on laboratory parameters and factors associated with death in meningitis, Kelantan Malaysia. Nagoya Journal of Medical Science. 2015; 77 (1-2):59-68 - 27.
Choi CH et al. Acinetobacter baumannii invades epithelial cells and outer membrane protein a mediates interactions with epithelial cells. BMC Microbiology. 2008;8 (1):1-11 - 28.
Choi CH et al. Acinetobacter baumannii outer membrane protein a targets the nucleus and induces cytotoxicity. Cellular Microbiology. 2008;10 (2):309-319 - 29.
Smani Y, Dominguez-Herrera J, Pachón J. Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii . The Journal of Infectious Diseases. 2013;208 (10):1561-1570 - 30.
Brossard KA, Campagnari AA. The Acinetobacter baumannii biofilm-associated protein plays a role in adherence to human epithelial cells. Infection and Immunity. 2012;80 (1):228-233 - 31.
Bentancor LV et al. Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii . Journal of Bacteriology. 2012;194 (15):3950-3960 - 32.
Pérez A et al. The FhaB/FhaC two-partner secretion system is involved in adhesion of Acinetobacter baumannii AbH12O-A2 strain. Virulence. 2017;8 (6):959-974 - 33.
Weidensdorfer M et al. The Acinetobacter trimeric autotransporter adhesin Ata controls key virulence traits of Acinetobacter baumannii . Virulence. 2019;10 (1):68-81 - 34.
Liou M-L et al. The sensor kinase BfmS mediates virulence in Acinetobacter baumannii . Journal of Microbiology, Immunology and Infection. 2014;47 (4):275-281 - 35.
Wood CR et al. A light-regulated type I pilus contributes to Acinetobacter baumannii biofilm, motility, and virulence functions. Infection and Immunity. 2018;86 (9):e00442-e00418 - 36.
Eijkelkamp BA et al. Adherence and motility characteristics of clinical Acinetobacter baumannii isolates. FEMS Microbiology Letters. 2011;323 (1):44-51 - 37.
Eijkelkamp BA et al. H-NS plays a role in expression of Acinetobacter baumannii virulence features. Infection and Immunity. 2013;81 (7):2574-2583 - 38.
Jacobs AC et al. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infection and Immunity. 2010;78 (5):1952-1962 - 39.
Smani Y et al. Platelet-activating factor receptor initiates contact of Acinetobacter baumannii expressing phosphorylcholine with host cells. Journal of Biological Chemistry. 2012;287 (32):26901-26910 - 40.
Lee C-R et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Frontiers in Cellular and Infection Microbiology. March 2017; 7 . Article ID: 55 - 41.
Erridge C et al. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via toll-like receptor 4 signalling. Journal of Medical Microbiology. 2007;56 (2):165-171 - 42.
McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii : Human infections, factors contributing to pathogenesis and animal models. FEMS Microbiology Reviews. 2013;37 (2):130-155 - 43.
Elhosseiny NM et al. γ-Glutamyltransferase as a novel virulence factor of Acinetobacter baumannii inducing alveolar wall destruction and renal damage in systemic disease. The Journal of Infectious Diseases. 2020;222 (5):871-879 - 44.
Ermis H et al. Relationship between serum γ-glutamyltransferase levels and acute exacerbation of chronic obstructive pulmonary disease. Polskie Archiwum Medycyny Wewnętrznej. 2013; 123 (3):85-90 - 45.
Carruthers MD et al. Acinetobacter baumannii utilizes a type VI secretion system for bacterial competition. PLoS One. 2013;8 (3):e59388 - 46.
Bannister BA, Begg NT, Gillespie SH. Infectious Disease. Oxford: Blackwell Science; 2000 - 47.
Kim SW et al. Outer membrane protein a plays a role in pathogenesis of Acinetobacter nosocomialis . Virulence. 2016;7 (4):413-426 - 48.
Russo TA et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infection and Immunity. 2010;78 (9):3993-4000 - 49.
Koenigs A et al. CipA of Acinetobacter baumannii is a novel plasminogen binding and complement inhibitory protein. The Journal of Infectious Diseases. 2016;213 (9):1388-1399 - 50.
Luke NR et al. Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis. Infection and Immunity. 2010;78 (5):2017-2023 - 51.
Fiester SE et al. Iron-regulated phospholipase C activity contributes to the cytolytic activity and virulence of Acinetobacter baumannii . PLoS One. 2016;11 (11):e0167068 - 52.
Zimbler DL et al. Stress response and virulence functions of the Acinetobacter baumannii NfuA Fe-S scaffold protein. Journal of Bacteriology. 2012;194 (11):2884-2893 - 53.
Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clinical Infectious Diseases. 2008; 46 (8):1254-1263 - 54.
Valencia R et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infection Control and Hospital Epidemiology. 2009;30 (3):257-263 - 55.
Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews. 2010; 74 (3):417-433 - 56.
Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy. 2010; 54 (3):969-976 - 57.
Hall BG, Barlow M. Revised ambler classification of β-lactamases. Journal of Antimicrobial Chemotherapy. 2005; 55 (6):1050-1051 - 58.
Perez F et al. Global challenge of multidrug-resistant Acinetobacter baumannii . Antimicrobial Agents and Chemotherapy. 2007;51 (10):3471-3484 - 59.
Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. The Journal of Antimicrobial Chemotherapy. 2010;65 (10):2253-2254 - 60.
Morán-Barrio J et al. The Acinetobacter outer membrane contains multiple specific channels for carbapenem β-lactams as revealed by kinetic characterization analyses of Imipenem permeation intoAcinetobacter baylyi cells. Antimicrobial Agents and Chemotherapy. 2017;61 (3):7 - 61.
Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii : Natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrobial Agents and Chemotherapy. 2005;49 (4):1432-1440 - 62.
Siroy A et al. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii . Antimicrobial Agents and Chemotherapy. 2005;49 (12):4876-4883 - 63.
Gribun A et al. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of Acinetobacter baumannii . Current Microbiology. 2003;47 (5):434-443 - 64.
Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii . The Journal of Antimicrobial Chemotherapy. 2007;59 (6):1210-1215 - 65.
Siroy A et al. Global comparison of the membrane subproteomes between a multidrug-resistant Acinetobacter baumannii strain and a reference strain. Journal of Proteome Research. 2006;5 (12):3385-3398 - 66.
Vashist J et al. Analysis of penicillin-binding proteins (PBPs) in carbapenem resistant Acinetobacter baumannii . The Indian Journal of Medical Research. 2011;133 (3):332-338 - 67.
Buckner MM et al. Beyond antimicrobial resistance: Evidence for a distinct role of the AcrD efflux pump in Salmonella biology. MBio. 2016;7 (6):1-2 - 68.
Yoon EJ et al. Contribution of the Ade resistance-nodulation-cell division-type efflux pumps to fitness and pathogenesis of Acinetobacter baumannii . MBio. 2016;7 (3):1-3 - 69.
Marchand I et al. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrobial Agents and Chemotherapy. 2004;48 (9):3298-3304 - 70.
Lee K et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrobial Agents and Chemotherapy. 2005;49 (11):4485-4491 - 71.
Shrestha S et al. Emergence of aminoglycoside resistance due to armA methylase in multi-drug resistant Acinetobacter Baumannii isolates in a University Hospital in Nepal. Journal of Nepal Health Research Council. 2016; 14 (33):72-76 - 72.
Lee H et al. Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea. Diagnostic Microbiology and Infectious Disease. 2006;56 (3):305-312 - 73.
Doi Y et al. Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. Antimicrobial Agents and Chemotherapy. 2007;51 (11):4209-4210 - 74.
Su XZ et al. AbeM, an H+-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrobial Agents and Chemotherapy. 2005;49 (10):4362-4364 - 75.
Ugolotti E et al. The whole genome sequencing of Acinetobacter-calcoaceticus-baumannii complex strains involved in suspected outbreak in an intensive care unit of a pediatric hospital. Journal of Hospital Administration. 2016;5 (6):81 - 76.
Charrier C et al. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases. The Journal of Antimicrobial Chemotherapy. 2016; 71 (10):2831-2839 - 77.
Yang H et al. Detection of the plasmid-mediated quinolone resistance determinants in clinical isolates of Acinetobacter baumannii in China. Journal of Chemotherapy. 2016;28 (5):443-445 - 78.
Bojkovic J et al. Characterization of an Acinetobacter baumannii lptD deletion strain: Permeability defects and response to inhibition of lipopolysaccharide and fatty acid biosynthesis. Journal of Bacteriology. 2015;198 (4):731-741 - 79.
Choi HJ et al. Characterisation of successive Acinetobacter baumannii isolates from a deceased haemophagocytic lymphohistiocytosis patient. International Journal of Antimicrobial Agents. 2017;49 (1):102-106 - 80.
Ribera A et al. Partial characterization of a transposon containing the tet(a) determinant in a clinical isolate of Acinetobacter baumannii . The Journal of Antimicrobial Chemotherapy. 2003;52 (3):477-480 - 81.
Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrobial Agents and Chemotherapy. 2001;45 (12):3375-3380 - 82.
Ribera A, Ruiz J, Vila J. Presence of the Tet M determinant in a clinical isolate of Acinetobacter baumannii . Antimicrobial Agents and Chemotherapy. 2003;47 (7):2310-2312 - 83.
Walsh TR et al. Metallo-beta-lactamases: The quiet before the storm? Clinical Microbiology Reviews. 2005; 18 (2):306-325 - 84.
Lob SH et al. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii . International Journal of Antimicrobial Agents. 2016;47 (4):317-323 - 85.
Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. The Lancet Infectious Diseases. 2008;8 (12):751-762 - 86.
Tal-Jasper R et al. Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrobial Agents and Chemotherapy. 2016;60 (5):3127-3131 - 87.
Jalali Y et al. Isolated carbapenem resistant bacteria, their multidrug resistant profile, percentage of healthcare associated infection and associated mortality, in hospitalized patients in a University Hospital in Bratislava. Bratislavské Lekárske Listy. 2021; 122 (6):379-385 - 88.
Thi Khanh Nhu N et al. The induction and identification of novel colistin resistance mutations in Acinetobacter baumannii and their implications. Scientific Reports. 2016;6 :28291 - 89.
Ozkan G et al. How does colistin-induced nephropathy develop and can it be treated? Antimicrobial Agents and Chemotherapy. 2013; 57 (8):3463-3469 - 90.
Abdellatif S et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: A prospective, randomised trial. Annals of Intensive Care. 2016; 6 (1):26 - 91.
Myint T et al. Respiratory muscle paralysis associated with colistin, polymyxin B, and muscle relaxants drugs: A case report. Journal of Investigative Medicine High Impact Case Reports. 2016; 4 (1):2324709616638362 - 92.
Silva A et al. Heteroresistance to colistin in Klebsiella pneumoniae is triggered by small colony variants sub-populations within biofilms. Pathogens and Disease. 2016;74 (5):1-2 - 93.
Zusman O et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: Systematic review and meta-analysis. The Journal of Antimicrobial Chemotherapy. 2017; 72 (1):29-39 - 94.
Cai Y et al. Colistin resistance of Acinetobacter baumannii : Clinical reports, mechanisms and antimicrobial strategies. The Journal of Antimicrobial Chemotherapy. 2012;67 (7):1607-1615 - 95.
Hong DJ et al. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagnostic Microbiology and Infectious Disease. 2016;86 (2):184-189 - 96.
Nepka M et al. In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrobial Agents and Chemotherapy. 2016;60 (11):6903-6906 - 97.
Hejnar P, Kolár M, Hájek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the teaching hospital in Olomouc. Acta Universitatis Palackianae Olomucensis Facultatis Medicae. 1999;142 :73-77 - 98.
Oikonomou O et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: Mechanisms of resistance, molecular identification and epidemiological data. BMC Infectious Diseases. 2015;15 :559 - 99.
Lashinsky JN et al. Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii : A review. Infectious Disease and Therapy. 2017;6 (2):199-211 - 100.
Lomovskaya O et al. Absence of TetB identifies minocycline-susceptible isolates of Acinetobacter baumannii . International Journal of Antimicrobial Agents. 2018;52 (3):404-406 - 101.
Hornsey M et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii . The Journal of Antimicrobial Chemotherapy. 2010;65 (8):1589-1593 - 102.
Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clinical Infectious Diseases. 2014; 59 (Suppl. 6 ):S374-S380 - 103.
Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Journal of Intensive Care Medicine. 2010;25 (6):343-348 - 104.
Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: A stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. Clinical Infectious Diseases. 2014;59 (Suppl. 6 ):S381-S387 - 105.
Lin NT et al. Isolation and characterization of phi AB2: A novel bacteriophage of Acinetobacter baumannii . Research in Microbiology. 2010;161 (4):308-314 - 106.
Aslam S et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open forum. Infectious Diseases. 2020; 7 (9):ofaa389 - 107.
Broncano-Lavado A et al. Advances in bacteriophage therapy against relevant multiDrug-resistant pathogens. Antibiotics. 2021; 10 (6):2-6 - 108.
Nielsen TB et al. Monoclonal antibody requires immunomodulation for efficacy against Acinetobacter baumannii infection. The Journal of Infectious Diseases. 2021;224 (12):2133-2147 - 109.
García-Quintanilla M et al. Emerging therapies for multidrug resistant Acinetobacter baumannii . Trends in Microbiology. 2013;21 (3):157-163 - 110.
Mohamed MF et al. A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii . Scientific Reports. 2017;7 (1):6953 - 111.
Luo G et al. Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia. European Journal of Clinical Microbiology & Infectious Diseases. 2014; 33 (5):845-851 - 112.
Czaplewski L et al. Alternatives to antibiotics-a pipeline portfolio review. The Lancet Infectious Diseases. 2016; 16 (2):239-251